Press Releases

ADDF Presents its September 2013 14th International Conference on Alzheimer’s Drug Discovery

08/20/2013

The Alzheimer’s Drug Discovery Foundation (ADDF) presents its annual fall conference, the 14th International Conference on Alzheimer’s Drug Discovery taking place on September 9-10, 2013 at the Hyatt Regency in Jersey City, NJ, across the Hudson River from New York City.

Read Release

The Hill Op-Ed: Dr. Fillit + Other Leaders in Alzheimer’s Community Comment on Amyvid Reimbursement

08/07/2013

Earlier this month, the Centers for Medicare and Medicaid Services (CMS) issued a draft Decision Memorandum to deny Medicare reimbursements to patients using an innovative FDA-approved Alzheimer's diagnostic technology designed to help physicians identify whether patients with signs of cognitive impairment may have Alzheimer's or are in fact suffering from another form of dementia. This information is vital to patients, their providers, choices regarding their treatment and their ultimate health outcomes.

The Alzheimer’s Drug Discovery Foundation Launches ADDF Access

07/01/2013

The Alzheimer's Drug Discovery Foundation (ADDF) today launched the ADDF ACCESS program to give the academic and small biotechnology communities online access to a marketplace of contract research organizations (CROs) and the industry standard preclinical drug discovery and development services they provide. Additionally, ADDF ACCESS offers educational resources and a network of expert consultants and collaborators who focus on drug discovery for diseases of the central nervous system (CNS) (http://www.alzdiscovery.org/research-and-grants/addf-access/).

ADDF Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate ApoE

06/12/2013

The Alzheimer’s Drug Discovery Foundation (ADDF) announced that it has awarded follow-on funding of $298,500 to Madera Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated beta-amyloid from the brain and thus halt or reverse the progression of Alzheimer’s disease.

Read Release

ADDF New York Times Letter To the Editor. Key to Fighting Alzheimer’s Costs: New Drugs

05/23/2013

Re “Dementia Study Predicts a Surge in Cost and Cases” (front page, April 4):

The projected costs of dementia care are staggering, but this has been known for decades. It’s time we paid more attention to one of the fastest-growing chronic diseases in our country.

Research Foundations Collaborate to Fund Ph 1 Study of Cancer Drug In Alzheimer’s Disease Patients

04/24/2013

The Alzheimer’s Drug Discovery Foundation (ADDF) and BrightFocus Foundation today announced a funding collaboration that will support a Phase I human clinical trial to evaluate the cancer drug bexarotene as a treatment for Alzheimer’s disease.

Read Release

Alzheimer’s Drug Discovery Foundation and Lewy Body Dementia Association Award Two Grants to Support

03/25/2013

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Lewy Body Dementia Association (LBDA) have awarded $100,000 each to Omar El-Agnaf, PhD, of United Arab Amirates University and Michelle Mielke, PhD, of Mayo Clinic Rochester to provide one year of support for their research projects focused on developing indicators, or biomarkers, for dementia with Lewy bodies (DLB).

Read Release

Alzheimer’s Drug Discovery Foundation Awards Grant To Cohbar To Develop A Novel Peptide Therapeutic

03/16/2013

The Alzheimer’s Drug Discovery Foundation (ADDF) announced today that it has awarded $205,260 in funding to CohBar Inc. to develop a novel mitochondrial peptide for the treatment of Alzheimer’s disease (AD). The peptide has been shown to have neuro-protective effects against a variety of AD-related toxic insults, including amyloid-beta.

Read Release

Research Foundations Collaborate to Fund Repository of Promising CNS-Active Compounds

02/28/2013

The Alzheimer’s Drug Discovery Foundation (ADDF), Beyond Batten Disease Foundation (BBDF) and the National Multiple Sclerosis Society today announced a funding collaboration to support the creation of the Collaborative CNS Screening Initiative (CCSI), a central repository of chemical compounds that have shown significant Central Nervous System (CNS) activity.

Read Release